Pony.ai CEO James Peng thinks robotaxis will be widespread within five years
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1037 ET – Apotex could find itself in a bind after President Trump’s threat to impose tariffs up to 200% on generic drugs made outside the U.S. Apotex, which recently went public, is down about 10% at C$35.72 as Trump says the levies would begin at 100% in August 2028 and rise a year later, giving drugmakers time to shift manufacturing. The plan targets generic medicines largely produced in India and China. Most of Apotex’s production is in Canada, with additional facilities in Mexico and India, and only two U.S. sites focused on warehousing, distribution and its U.S. affiliate headquarters. ([email protected])
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
investment News
newsplus,Pharmaceuticals,Healthcare/Life Sciences,Generic/Biosimilar Drugs,Manufacturing,Dragonfly – North America,Dragonfly – World,North America,United States,Trade/External Payments,Economic News,Political/General News,International Relations,Health/Medicine,Politics/International Relations,Trade Barriers/Restrictions,SYND,WSJ-PRO-WSJ.com,GCAPI,LINK:EN|drn:realtime.linkedarticle.DNCO20260722006494,trade,external payments,political,general news,health,medicine,politics,trade barriers,restrictions,healthcare,life sciences,generic,biosimilar drugs
